158 related articles for article (PubMed ID: 3034708)
21. Analysis of the immune response against mixotope peptide libraries from a main antigenic site of foot-and-mouth disease virus.
Oliveira Ed; Jiménez-Clavero MA; Núñez JI; Sobrino F; Andreu D
Vaccine; 2005 Apr; 23(20):2647-57. PubMed ID: 15780448
[TBL] [Abstract][Full Text] [Related]
22. Synthetic peptides against foot-and-mouth disease--immunization with VP1-peptides of type O1-Kaufbeuren.
Liebermann H; Holl U; Reimann I; Nöckler A; Schäfer D; Thalmann G; Dölling R
Arch Exp Veterinarmed; 1990; 44(6):883-90. PubMed ID: 1966360
[TBL] [Abstract][Full Text] [Related]
23. Antigenically profound amino acid substitutions occur during large population passages of foot-and-mouth disease virus.
Sevilla N; Verdaguer N; Domingo E
Virology; 1996 Nov; 225(2):400-5. PubMed ID: 8918927
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies to an Indian strain of type A foot-and-mouth disease virus.
Tosh C; Venkataramanan R; Pattnaik B; Hemadri D; Sanyal A
Acta Virol; 1999 Aug; 43(4):219-25. PubMed ID: 10749367
[TBL] [Abstract][Full Text] [Related]
25. The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease.
Dunn CS; Samuel AR; Pullen LA; Anderson J
Virology; 1998 Jul; 247(1):51-61. PubMed ID: 9683571
[TBL] [Abstract][Full Text] [Related]
26. [Antigenic structure of the foot-and-mouth disease virus. II. Synthesis of protective peptides from the major immunogenic region of VP1 protein of foot-and-mouth disease virus type A22].
Vol'pina OM; Surovoĭ AIu; Ul'iashin VV; Ivanov VT; Chepurkin AV
Bioorg Khim; 1988 Oct; 14(10):1363-71. PubMed ID: 2852938
[TBL] [Abstract][Full Text] [Related]
27. Enhanced immunogenicity and cross-reactivity of retro-inverso peptidomimetics of the major antigenic site of foot-and-mouth disease virus.
Muller S; Guichard G; Benkirane N; Brown F; Van Regenmortel MH; Briand JP
Pept Res; 1995; 8(3):138-44. PubMed ID: 7670228
[TBL] [Abstract][Full Text] [Related]
28. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.
Parry NR; Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F
J Gen Virol; 1989 Jun; 70 ( Pt 6)():1493-503. PubMed ID: 2471812
[TBL] [Abstract][Full Text] [Related]
29. Molecular dynamics of the alpha-helical epitope of a novel synthetic lipopeptide foot-and-mouth disease virus vaccine.
Krug M; Folkers G; Haas B; Hess G; Wiesmüller KH; Freund S; Jung G
Biopolymers; 1989 Jan; 28(1):499-512. PubMed ID: 2470437
[TBL] [Abstract][Full Text] [Related]
30. Qualitative and quantitative differences in the immune response to foot-and-mouth disease virus antigens and synthetic peptides.
Francis MJ; Fry CM; Rowlands DJ; Brown F
J Gen Virol; 1988 Oct; 69 ( Pt 10)():2483-91. PubMed ID: 2844964
[TBL] [Abstract][Full Text] [Related]
31. DNA vaccination against foot-and-mouth disease via electroporation: study of molecular approaches for enhancing VP1 antigenicity.
Kim SA; Liang CM; Cheng IC; Cheng YC; Chiao MT; Tseng CJ; Lee F; Jong MH; Tao MH; Yang NS; Liang SM
J Gene Med; 2006 Sep; 8(9):1182-91. PubMed ID: 16927362
[TBL] [Abstract][Full Text] [Related]
32. Neutralization antigenic sites on type Asia-1 foot-and-mouth disease virus defined by monoclonal antibody-resistant variants.
Butchaiah G; Morgan DO
Virus Res; 1997 Dec; 52(2):183-94. PubMed ID: 9495534
[TBL] [Abstract][Full Text] [Related]
33. Pseudorabies virus glycoprotein B can be used to carry foot and mouth disease antigens in DNA vaccination of pigs.
Dory D; Rémond M; Béven V; Cariolet R; Backovic M; Zientara S; Jestin A
Antiviral Res; 2009 Mar; 81(3):217-25. PubMed ID: 19103226
[TBL] [Abstract][Full Text] [Related]
34. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants.
Taboga O; Tami C; Carrillo E; Núñez JI; Rodríguez A; Saíz JC; Blanco E; Valero ML; Roig X; Camarero JA; Andreu D; Mateu MG; Giralt E; Domingo E; Sobrino F; Palma EL
J Virol; 1997 Apr; 71(4):2606-14. PubMed ID: 9060612
[TBL] [Abstract][Full Text] [Related]
35. The potential of retro-inverso peptides as synthetic vaccines.
Van Regenmortel MH; Guichard G; Benkirane N; Briand JP; Muller S; Brown F
Dev Biol Stand; 1998; 92():139-43. PubMed ID: 9554267
[TBL] [Abstract][Full Text] [Related]
36. [Antigenic structure of the foot-and-mouth-disease virus. I. Synthesis of protective peptides from the major immunogenic region of VP1 protein of foot-and-mouth virus type O1K].
Surovoĭ AIu; Vol'pina OM; Snetkova EV; Volkova TD; Ivanov VT
Bioorg Khim; 1988 Oct; 14(10):1352-62. PubMed ID: 2852937
[TBL] [Abstract][Full Text] [Related]
37. Analysis of immune responses in the sheep to synthetic peptides of foot-and-mouth disease virus using ovine polyclonal and monoclonal antibodies.
Flynn JN; Harkiss GD; Doel T; DiMarchi R
Immunology; 1990 Jan; 69(1):1-7. PubMed ID: 1690176
[TBL] [Abstract][Full Text] [Related]
38. Antibodies raised in a natural host and monoclonal antibodies recognize similar antigenic features of foot-and-mouth disease virus.
Mateu MG; Andreu D; Domingo E
Virology; 1995 Jun; 210(1):120-7. PubMed ID: 7793064
[TBL] [Abstract][Full Text] [Related]
39. Protection of mice against challenge with foot and mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1.
Wigdorovitz A; Pérez Filgueira DM; Robertson N; Carrillo C; Sadir AM; Morris TJ; Borca MV
Virology; 1999 Nov; 264(1):85-91. PubMed ID: 10544132
[TBL] [Abstract][Full Text] [Related]
40. Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants.
Stave JW; Card JL; Morgan DO; Vakharia VN
Virology; 1988 Jan; 162(1):21-9. PubMed ID: 2827379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
